Arca
Skip to content
Tools
Tools

VKORC1: Vitamin K epoxide reductase complex subunit 1

Involved in vitamin K metabolism.

  • Drugs that act on it: 6
  • Approved: 5
  • In phases 1 to 3: 1
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on VKORC1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 6

Approved5

  • Warfarin
  • Acenocoumarol
  • Phenprocoumon
  • Phenindione
  • Dicumarol

Phase 31

  • Tecarfarin

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • ARYx Therapeutics117%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor.
      WarfarinBoxed warningApprovedSanofiSmall moleculeInhibitor82
      AcenocoumarolApprovedSanofiSmall moleculeInhibitor4
      PhenprocoumonApprovedOrganonSmall moleculeInhibitor2
      PhenindioneApprovedSanofiSmall moleculeInhibitor1
      DicumarolApprovedEli LillySmall moleculeInhibitor0
      TecarfarinPhase 3ARYx TherapeuticsSmall moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.
      An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesWarfarinPhase 1Not yet recruitingSanofiNov 6, 2026
      Post Pulmonary Embolism In Patients Treated With Catheter Based TherapyWarfarinNot applicableNot yet recruitingAssiut UniversityOct 21, 2026
      Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid SyndromeAcenocoumarol, WarfarinPhase 3Not yet recruitingAssistance Publique - Hôpitaux de ParisOct 15, 2026
      A Study on Abnormal Menstrual Bleeding in Chinese Women of Childbearing Age Taking Antithrombotic Drugs After Cardiovascular SurgeryWarfarin—RecruitingShanghai Zhongshan HospitalOct 13, 2026
      Warfarin Quality, Adherence, Range, Determinants, and Events in Egyptian Rheumatic Heart Disease and Atrial FibrillationWarfarin—Not yet recruitingAssiut UniversitySep 17, 2026
      Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or ObesityWarfarinPhase 1RecruitingThe United Bio-Technology (Hengqin) Co., Ltd.Aug 25, 2026
      Predicting Response and Exposure Changes in Cirrhosis for EffectivenessWarfarinNot applicableNot yet recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Aug 6, 2026
      Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic StrokeWarfarinPhase 3Not yet recruitingAsan Medical CenterJul 28, 2026
      Antithrombotic Treatment Strategies in Cervical Artery DissectionPhenprocoumon, AcenocoumarolNot applicableNot yet recruitingUniversity Department of Geriatric Medicine FELIX PLATTERJun 10, 2026
      Anticoagulation Therapy in Non-device-related Intra-cardiac ThrombusAcenocoumarolPhase 3Active, not recruitingCentre Hospitalier Universitaire de NīmesApr 24, 2023
      Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APSPhenindione, Phenprocoumon, Acenocoumarol—RecruitingMcMaster UniversityDec 12, 2022

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Hereditary combined deficiency of vitamin K-dependent clotting factors0.72
      • Vitamin K-dependent clotting factors, combined deficiency of, type 20.72
      • Thrombotic disease0.60
      • Stroke disorder0.56
      • Recurrent thrombophlebitis0.54
      • Neurodegenerative disease0.44

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1930, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9BQB6, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.